Natural Compound Apigenin Targets Senescent Cells to Combat Aging and Cancer

This groundbreaking study addresses one of aging's fundamental challenges: the accumulation of senescent cells that drive age-related diseases and dysfunction. Senescent cells, while beneficial in wound healing and development, become harmful when they persist and secrete inflammatory factors called the senescence-associated secretory phenotype (SASP).

Researchers conducted a comprehensive screening of 66 natural medicinal compounds to identify agents that could modulate senescent cell behavior. They discovered that apigenin, a dietary flavonoid abundant in fruits and vegetables, acts as a potent senomorphic agent—meaning it suppresses the harmful inflammatory activity of senescent cells without killing them.

The team uncovered apigenin's mechanism of action: it directly targets peroxiredoxin 6 (PRDX6), a cellular protein involved in oxidative stress responses. By inhibiting PRDX6's phospholipase activity, apigenin disrupts the molecular cascade that leads to SASP development, specifically blocking interactions between key stress-response proteins ATM, p38MAPK, and HSPA8.

In laboratory studies, apigenin reduced cancer cell aggressiveness when combined with chemotherapy and prevented chemotherapy resistance. Most remarkably, in mouse models of premature aging, apigenin treatment improved physical function, reduced frailty, and enhanced cognitive performance—demonstrating broad geroprotective effects.

These findings are particularly significant because apigenin is already present in the human diet and has an established safety profile, potentially accelerating its path to clinical applications. The research provides compelling evidence that targeting senescent cells through natural compounds could offer a practical approach to healthy aging and age-related disease prevention.